PFO
PTCT icon

Pathstone Family Office’s PTC Therapeutics PTCT Stock Holding History

Pathstone Family Office’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-28
Closed -$1K – 952
2020
Q2 		$1K Sell
28
-40
-59% -$1.97K ﹤0.01% 683
2020
Q1 		$3K Buy
+68
New +$3.42K ﹤0.01% 668
2019
Q4 		– Sell
-28
Closed -$1K – 577
2019
Q3 		$1K Buy
+28
New +$1.22K ﹤0.01% 593

Other funds holding PTCT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Pathstone Family Office's PTCT Position: Q3 2020 in Review

Pathstone Family Office sold out of PTC Therapeutics (PTCT) in Q3 2020, closing a stake of 28 shares — an estimated $1K sold.

Pathstone Family Office first reported a position in PTCT in Q3 2019 and held it in 3 quarters. The position peaked at $3K in Q1 2020. 196 funds tracked by Wall St. Rank hold PTCT as of Q3 2020.

  • Pathstone Family Office reported no remaining PTC Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Pathstone Family Office sold 28 PTC Therapeutics shares in Q3 2020, an estimated $1K.
  • Pathstone Family Office first reported a position in PTC Therapeutics in Q3 2019 and held it in 3 quarters.
  • Pathstone Family Office's PTC Therapeutics position peaked at $3K in Q1 2020.
  • 196 funds tracked by Wall St. Rank held PTC Therapeutics as of Q3 2020.

Based on Pathstone Family Office's 13F filing for Q3 2020, filed 12 Nov 2020.